|
The random administration of estrogens associated or not
with progesterone or progestogens HRT (hormonal replacement
therapy) are dedicated to failure and have even noxious
effects.
FAILURE OF “HORMONAL TREATMENTS” (HRT = Hormonal Replacement
Therapy) AMONG MENOPAUSED WOMEN
The “WOMENS' HEALTH
INITIATIVE”
is a15-year project involves over 161,000 women ages 50-79,
and is one of the most definitive, far reaching programs of
research on women's health ever undertaken in the U.S.
(http://www.whi.org
)
Results of the first HRT study on “Risks and Benefits of
Estrogen Plus Progestin in Healthy Postmenopausal Women”
were published in 2002 (JAMA.
2002;288:321-333)
(5).
The conclusions
about this randomized clinical trial of great scale relating
to 16,608 old women from 50 to 79 years treated by Progestin
(2.5 mg of medroxyprogesterone acetate) and estrogens (0,625
Mg of combined estrogens “equine”) were: (table 5).
The study was to proceed until 2005. It was stopped after a
5.2 years average of follow-up on July 9th, 2002.
It was decided to continue the treatment containing
estrogens alone among women with prior hysterectomy
http://www.whi.org
WOMEN WITH PRIOR HYSTERECTOMY
aged 50-79 years
The Women’s Health Initiative (WHI) Estrogen Alone (E-Alone)
Trial was designed to assess the health benefits and risks
of estrogen use in healthy postmenopausal women. In the WHI
E-Alone Trial, 10,739 women with prior hysterectomy, aged
50-79 years, were assigned to take either estrogen alone
(conjugated estrogens [Premarin®]) or inactive (placebo)
study pills. The National Institutes of Health stopped the
E-Alone Trial ahead of schedule in February 2004 primarily
because of an increased stroke risk for women
taking study pills with estrogen alone
The pharmaceutical industry
·
Even after the Women's Health Initiative (WHI) found
that the risks of menopausal hormone therapy (hormone
therapy) outweighed benefit for asymptomatic women, about
half of gynecologists in the United States continued to
believe that hormones benefited women's health.
The pharmaceutical industry has supported publication of
articles in medical journals for marketing purposes (6).
·
In June 2011
the U.S. Supreme Court refused to hear a Pfizer Inc. unit’s
appeal of a $58 million award in a case against
Premarin
(estrogens)
and
Prempro
(estrogens plus medroxyprogesterone acetate)
menopause drugs.
Three Nevada women who contracted breast cancer after taking
the company’s menopause drugs were awarded the amount in a
2007 case.
·
The rebuff leaves the amount as the largest to be upheld on
appeal in thousands of hormone-replacement drug suits. Over
six million women took Prempro and other menopause drugs
before a 2002 study pointed out their links to cancer. At
one point Pfizer and his units faced more than 10,000
claims, according to lawyers for former users
G. Debled. The
menopause disease.
Approaches
to aging control : 19:17-24,October
2015
The menopause
disease .pdf
Octobre 2015.
SEMAL Madrid
|
.jpg){kind=small}
.png){kind=small}
